DGX at a glance
Quest Diagnostics (DGX, SEC CIK 1022079) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Quest Diagnostics (DGX) reported revenue of $11.0 billion (up 11.8% from FY2024) and net income of $992.0 million. Diluted EPS was $8.75.
- As of June 30, 2026, 44 institutional investment managers tracked by SignalX reported holding Quest Diagnostics (DGX) shares worth $11.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Davis J. E. on September 1, 2026 of 10,000 shares at $242.72 per share.
- In the last 90 days, DGX insiders reported 0 open-market purchases ($0) and 5 open-market sales ($8.3M) on Form 4, a net sale of $8.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $11.0B
- +11.8% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$8.3M
- 13F holders
- 44 funds
- $11.3B · +1 vs prior quarter
- Latest 8-K
- Jul 23, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $11.0B in FY2025; no explicit YoY dollar comparison provided in the MD&A text
- Advanced Diagnostics segment: oncology, cardiometabolic, brain health, autoimmune, women's health/genetics, exceeded $1B revenue on double-digit growth
- Hospital channel: reference testing ~$1.2B; Collaborative Lab Solutions ~$800M in 2025
- Capital return: quarterly dividend raised ~7.5% to $0.86/share; ~$8.1B returned via buybacks since 2012
- Key risks: PAMA reimbursement reform pending, Project Nova IT modernization through 2031–2032, and evolving AI/regulatory landscape
Risk Factors
- PAMA reimbursement reform risk: Congress introduced 2025 Results Act to fix structural flaws; prior 2018-2020 cuts exceeded original 10-year savings projections
- Debt load $5.7B outstanding as of Dec 31, 2025 with restrictive covenants limiting operational flexibility
- IT modernization via multi-year Project Nova, partnered with Epic; system failure could disrupt billing and customer service operations
- AI-enabled point-of-care and home testing competitors threatening volume; hospitals internalizing advanced testing without commercial labs
- Tariffs and trade policy uncertainty raising supply chain costs for testing equipment and materials across international operations
Business Overview
- Largest national lab services provider: ~$11.0B net revenue in 2025, serving ~⅓ of U.S. adult population annually and processing 244 million test requisitions
- Advanced Diagnostics™ five-franchise segment (oncology, cardiometabolic, brain health, autoimmune, women's health) surpassed $1B revenue on double-digit growth
- Haystack Oncology MRD ctDNA test received FDA Breakthrough Device Designation in 2025 for early-stage colorectal cancer, with clinical trials launched at Mass General Brigham and Rutgers Cancer Institute
- Project Nova launched Feb 2025: multi-year Epic-powered "Order to Cash" modernization targeting completion 2031–2032; Google Cloud generative AI collaboration also announced in 2025
- LifeLabs acquisition (2024) added ~6,800 employees and ~23 million Canadian test requisitions in first full year, bringing global headcount to nearly 57,000
AI summary of the DGX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $3,043M, up 10.2% YoY from $2,761M, driven by DIS revenue growth
- Operating margin 15.1% vs 15.9% YoY; net income $320M vs $282M
- Best segment DIS revenue $2,978M, up 10.3%; DS revenue $65M, up 4.3%
- Operating cash flow $597M vs $544M; capital expenditures $138M vs $108M
- $500M 5.00% senior notes issued; $500M 3.45% notes repaid at maturity
- Near-term headwinds: compensation costs, reimbursement pressures, inflation, and revenue per requisition down 2.8%
Risk Factors
- Risk factors section not provided in submitted filing text
- No new, changed, regulatory, operational, competitive, market, or financial risk disclosed in provided excerpt
AI summary of the DGX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Quest Diagnostics reported results for quarter ended June 30, 2026
- Press release contains financial results and related disclosures in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $3.04B, up 10.2%, with 10.0% organic growth and requisition volume up 13.1%
- Reported diluted EPS $2.84, up 15.0%; adjusted EPS $3.12, up 19.1%
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 11 director nominees elected, with support ranging from 81,917,543 to 93,909,369 votes
- Executive compensation advisory vote approved, 86,869,738 FOR versus 7,152,448 AGAINST
AI summaries of DGX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DGX
Don't miss the next DGX filing
- Alerts as it files. A push when DGX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DGX, by share count.
- Ask anything. An AI agent that reads every DGX filing and answers with sources.
DGX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| WENTWORTH TIMOTHY C | A | Oct 1, 2026 | 135 | - |
| Davis J. E. | Sell | Sep 1, 2026 | 10,000 | $242.72 |
| PREVOZNIK MICHAEL E | M | Aug 28, 2026 | 22,677 | $112.17 |
| PREVOZNIK MICHAEL E | Sell | Aug 28, 2026 | 430 | $244.51 |
| PREVOZNIK MICHAEL E | G | Aug 28, 2026 | 1,000 | - |
| PREVOZNIK MICHAEL E | Sell | Aug 28, 2026 | 6,237 | $243.63 |
| PREVOZNIK MICHAEL E | Sell | Aug 28, 2026 | 16,010 | $242.88 |
| PREVOZNIK MICHAEL E | M | Aug 28, 2026 | 22,677 | $112.17 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $9.9B | $11.0B |
| Operating Income | - | $1.3B | $1.6B |
| Net Income | $854.0M | $871.0M | $992.0M |
| Op. Margin | - | 13.6% | 14.1% |
| Net Margin | - | 8.8% | 9.0% |
| Balance Sheet | |||
| Total Assets | - | $16.2B | $16.2B |
| Equity | $6.3B | $6.8B | $7.2B |
| ROE | 13.5% | 12.9% | 13.8% |
| Per Share | |||
| EPS | $7.49 | $7.69 | $8.75 |
| Cash Flow | |||
| Operating CF | - | $1.3B | $1.9B |
| CapEx | $408.0M | $425.0M | $527.0M |
Source: XBRL data in Quest Diagnostics (DGX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DGX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 44 | $11.35B |
| Q1 2026 | 43 | $10.72B |
| Q4 2025 | 40 | $9.99B |
| Q3 2025 | 41 | $11.76B |
| Q2 2025 | 40 | $10.34B |
| Q1 2025 | 38 | $6.37B |
| Q4 2024 | 32 | $4.66B |
| Q3 2024 | 30 | $2.45B |
- FMR LLC (Fidelity)+456.5K (+48%)
- Bank of America Corp+182.2K (+10%)
- State Street Corp+135.8K (+3%)
- BlackRock+103.1K (+1%)
- Vanguard Capital Management LLC+87.7K (+1%)
- T. Rowe Price Group−853.0K (-14%)
- Goldman Sachs Group−366.0K (-27%)
- JPMorgan Chase & Co−326.0K (-8%)
- Invesco Ltd−259.4K (-16%)
- Citadel Advisors LLC−214.0K (-62%)
- Marex Group plc+1.8K
- Citizens Financial Group+1.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 308 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DGX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 6, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
DGX SEC filings: frequently asked questions
Are DGX insiders buying or selling?
In the last 90 days, Quest Diagnostics (DGX) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $8.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DGX stock?
As of June 30, 2026, the largest Quest Diagnostics (DGX) holders among the 13F filers tracked by SignalX were BlackRock ($2.0 billion), Vanguard Capital Management LLC ($1.5 billion), Vanguard Portfolio Management LLC ($1.3 billion), State Street Corp ($1.2 billion), T. Rowe Price Group ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DGX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Quest Diagnostics (DGX) reported revenue of $11.0 billion (up 11.8% from FY2024) and net income of $992.0 million. Diluted EPS was $8.75. The figures come from the XBRL data in the 10-K.
What are the main risks in DGX's latest 10-K?
In the 10-K filed February 26, 2026, Quest Diagnostics (DGX) flagged: PAMA reimbursement reform risk: Congress introduced 2025 Results Act to fix structural flaws; prior 2018-2020 cuts exceeded original 10-year savings projections. Debt load $5.7B outstanding as of Dec 31, 2025 with restrictive covenants limiting operational flexibility. (AI summary of the Risk Factors section.)
What did DGX report in its latest 8-K?
Quest Diagnostics (DGX) filed an 8-K on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Quest Diagnostics reported results for quarter ended June 30, 2026.
What are the latest DGX SEC filings?
Quest Diagnostics (DGX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on October 2, 2026.
What is DGX's SEC CIK number?
Quest Diagnostics (DGX)'s SEC Central Index Key (CIK) is 1022079. EDGAR lists every DGX filing under that number.
Ask anything about DGX
The research agent reads DGX's filings, financials, insider trades and 13F holders, then answers with sources.